-
1.发明申请Solid Oral Dosage Forms of Ziprasidone Containing Colloidal Silicone Dioxide 审中-公开含有胶体硅氧烷的齐拉西酮的固体口服剂型公开(公告)号：US20080268034A1
公开(公告)日：2008-10-30
申请号：US11813298
申请日：2006-01-06
IPC分类号： A61K9/48 , A61K9/14 , A61K31/501 , A61P25/18 , A61K9/20
CPC分类号： A61K31/496 , A61K9/1611 , A61K9/2009
摘要： The present invention relates to solid oral dosage forms of ziprasidone and salts thereof and processes for their preparation, containing colloidal silicon dioxide.
摘要翻译： 本发明涉及齐拉西酮及其盐的固体口服剂型及其制备方法，含有胶体二氧化硅。
-
2.发明申请Methods For the Preparation of Stable Pharmaceutical Solid Dosage Forms of Atorvastatin and Amlodipine 审中-公开阿托伐他汀和氨氯地平稳定药物固体剂型的制备方法公开(公告)号：US20080305158A1
公开(公告)日：2008-12-11
申请号：US11722620
申请日：2005-12-22
CPC分类号： A61K31/40 , A61K9/2009 , A61K9/2018 , A61K9/2054 , A61K9/2077 , A61K31/4422 , A61K2300/00
摘要： The present invention relates to pharmaceutical compositions comprising amlodipine and pharmaceutically acceptable salts thereof, and atorvastatin and pharmaceutically acceptable salts thereof, and processes for their preparation.
摘要翻译： 本发明涉及包含氨氯地平及其药学上可接受的盐，阿托伐他汀及其药学上可接受的盐的药物组合物及其制备方法。
-
公开(公告)号：US07115281B2
公开(公告)日：2006-10-03
申请号：US10616240
申请日：2003-07-08
申请人： Romi Barat Singh , Pannanchukunnath Manoj Kumar , Vishnubhotla Nagaprasad , Sunilendu Bhushan Roy , Rajiv Malik
发明人： Romi Barat Singh , Pannanchukunnath Manoj Kumar , Vishnubhotla Nagaprasad , Sunilendu Bhushan Roy , Rajiv Malik
CPC分类号： A61K9/2059 , A61K9/14 , A61K9/2018 , A61K9/2027 , A61K9/2054 , A61K31/165
摘要： The invention relates to processes for preparing, and pharmaceutical compositions of, modafinil dosage forms for oral administration. The dosage forms include a mixture of coarse and fine particles of modafinil. The process for preparing modafinil oral dosage forms includes forming a dosage form that includes about 7%–25% by weight of modafinil particles having diameters greater than 220 μm and about 75%–93% by weight of modafinil particles having diameters less than 220 μm.
摘要翻译： 本发明涉及用于口服给药的莫达非尼剂型的制备方法和药物组合物。 剂型包括莫达非尼的粗颗粒和细颗粒的混合物。 莫替非尼口服剂型的制备方法包括形成剂型，其包含约7％-25％重量的直径大于220μmm和约75％-93％的直径小于220μmm的莫达非尼颗粒的莫达非尼颗粒 。
-
4.发明申请公开(公告)号：US20080044468A1
公开(公告)日：2008-02-21
申请号：US10522223
申请日：2003-07-24
申请人： Romi Barat Singh , Pananchukunnath Manoj Kumar , Vishnubhotla Nagaprasad , Sunilendu Bhshan Roy , Rajiv Malik
发明人： Romi Barat Singh , Pananchukunnath Manoj Kumar , Vishnubhotla Nagaprasad , Sunilendu Bhshan Roy , Rajiv Malik
IPC分类号： A61K9/48 , A61K31/165 , A61K9/14 , A61P43/00 , A61K9/20
CPC分类号： A61K9/2009 , A61K9/2013 , A61K9/2018 , A61K9/2027 , A61K9/2054 , A61K9/2059
摘要： The present invention relates to a method for the preparation of bioavailable dosage form of modafinil.
摘要翻译： 本发明涉及一种制备莫达非尼的生物可利用剂型的方法。
-
5.发明申请Stable Oral Benzimidazole Compositions Prepared by Non-Aqueous Layering Process 审中-公开通过非水层析法制备稳定的口服苯并咪唑组合物公开(公告)号：US20080279951A1
公开(公告)日：2008-11-13
申请号：US11815160
申请日：2006-02-02
IPC分类号： A61K9/14 , A61K31/4184 , A61K31/4439
CPC分类号： A61K9/5078 , A61K9/2081 , A61K9/5026 , A61K9/5047 , A61K31/4439
摘要： The present invention relates to processes for the preparation of stable oral compositions of benzimidazole compounds prepared using a non-aqueous layering process.
摘要翻译： 本发明涉及制备使用非水分层方法制备的稳定的苯并咪唑化合物口服组合物的方法。
-
6.发明申请公开(公告)号：US20060210620A1
公开(公告)日：2006-09-21
申请号：US10542587
申请日：2004-01-21
CPC分类号： A61K31/4178 , A61K9/1635 , A61K9/2077 , A61K31/4174
摘要： The technical field of the invention relates to spray dried, co-precipitate amorphous losartan dosage forms that are stable over time and processes for their preparation. The processes stabilize the amorphous losartan. The process includes preparing an aqueous solution of losartan and one or more hydrophilic polymers; and spray drying the aqueous solution of losartan and one or more hydrophilic polymers to form a mixture. The amorphous losartan and one or more hydrophilic polymers are co-precipitated from the aqueous solution.
摘要翻译： 本发明的技术领域涉及随时间稳定的喷雾干燥，共沉淀的无定形氯沙坦剂型，其制备方法。 该方法稳定无定形氯沙坦。 该方法包括制备氯沙坦和一种或多种亲水聚合物的水溶液; 并喷雾干燥氯沙坦水溶液和一种或多种亲水聚合物以形成混合物。 无定形氯沙坦和一种或多种亲水聚合物从水溶液中共沉淀。
-
7.发明申请公开(公告)号：US20090162449A1
公开(公告)日：2009-06-25
申请号：US11722731
申请日：2005-12-22
IPC分类号： A61K9/14 , A61K31/435
CPC分类号： A61K31/4439 , A61K9/5026 , A61K9/5047 , A61K9/5078
摘要： The present invention relates to stable oral compositions of one or more benzimidazole compounds and processes for their preparation. Also provided are methods for treating various gastrointestinal disorders.
摘要翻译： 本发明涉及一种或多种苯并咪唑化合物的稳定的口服组合物及其制备方法。 还提供了治疗各种胃肠道疾病的方法。
-
公开(公告)号：US20070167380A1
公开(公告)日：2007-07-19
申请号：US10509824
申请日：2003-04-03
IPC分类号： A61K31/7048 , A61K31/734
CPC分类号： A61K31/4439 , A61K9/1652 , A61K9/1676 , A61K9/5078 , A61K31/43 , A61K31/7048 , A61K31/734 , A61K2300/00
摘要： A pharmaceutical composition includes erythromycin A or a derivative thereof and alginic acid. The alginic acid provides taste masking of the erythromycin A or derivative. The erythromycin A derivative may be clarithromycin and the alginic acid may be one or both of alginic acid and its salt. The salt may be one or more of sodium alginate and calcium alginate. The pharmaceutical composition may further include one or more of a binder, a disintegrant, a flavoring agent, and a coating. The pharmaceutical composition also may include one or more active ingredients, including omeprazole, metronidazole, amoxicillin, rifampicin, lansoprazole, ciprofloxacin, ethambutol, and ritonavir. The erythromycin A or a derivative thereof and the one or more active ingredients may be combined in a single pharmaceutical composition.
摘要翻译： 药物组合物包括红霉素A或其衍生物和藻酸。 藻酸提供红霉素A或衍生物的掩味。 红霉素A衍生物可以是克拉霉素，海藻酸可以是藻酸及其盐中的一种或两种。 该盐可以是海藻酸钠和藻酸钙中的一种或多种。 药物组合物还可以包括粘合剂，崩解剂，调味剂和涂层中的一种或多种。 药物组合物还可以包括一种或多种活性成分，包括奥美拉唑，甲硝唑，阿莫西林，利福平，兰索拉唑，环丙沙星，乙胺丁醇和利托那韦。 红霉素A或其衍生物和一种或多种活性成分可以在单一药物组合物中组合。
-
公开(公告)号：US20060002997A1
公开(公告)日：2006-01-05
申请号：US10525534
申请日：2003-08-25
CPC分类号： A61K9/4808 , A61K9/2027 , A61K9/2054 , A61K9/5084 , A61K31/4178
摘要： The present invention generally relates to controlled release dosage forms which provide immediate release and sustained release of nitrofurantoin, and processes for their preparation. The controlled release dosage form includes a sustained release portion and an immediate release portion. The sustained release portion includes nitrofurantoin and one or more pH dependent hydrophilic polymers. The immediate release portion includes nitrofurantoin.
摘要翻译： 本发明一般涉及提供呋喃妥因立即释放和持续释放的控释剂型及其制备方法。 控释剂型包括持续释放部分和立即释放部分。 持续释放部分包括呋喃妥因和一种或多种pH依赖性亲水性聚合物。 即时释放部分包括呋喃妥因。
-
公开(公告)号：US6074669A
公开(公告)日：2000-06-13
申请号：US984733
申请日：1997-12-04
CPC分类号： A61K9/2054
摘要： A pharmaceutical composition in the form of a tablet or a capsule for the controlled release of diltiazem, comprises about 30 to about 97% by weight of a hydrophilic polymer, about 0.5 to about 30% by weight of an enteric (pH-dependent) polymer, and about 2.5 to about 60% by weight of diltiazem or a pharmaceutically acceptable salt or ester thereof. The ratio of hydrophilic polymer to enteric polymer is in the range of about 1:1 to about 15:1. Such a pharmaceutical composition releases diltiazem at a rate that allows effective plasma levels of diltiazem to be maintained over a period of twenty-four hours after administration to human adult subjects.
摘要翻译： 片剂或胶囊形式的用于控制地尔硫卓的药物组合物包含约30至约97重量％的亲水性聚合物，约0.5至约30重量％的肠溶（pH依赖性）聚合物 ，和约2.5至约60重量％的地尔硫卓或其药学上可接受的盐或酯。 亲水性聚合物与肠溶性聚合物的比率在约1:1至约15:1的范围内。 这样的药物组合物以给予人成年受试者的二十四小时内维持有效血浆水平的地尔硫卓的速度释放地尔硫卓。
-
-
-
-
-
-
-
-
-
搜索结果
14 条记录 (耗时 0.017 秒)
